Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study) Meeting Abstract
| Authors: | Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grunwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Kopyltsov, E.; Vidal, M. J. M.; Hong, S. H.; Kapoor, A.; Gordoa, T. A.; Goh, J. C.; Merchan, J. R.; Smith, A. D.; Mody, K.; Perini, R. F.; Xing, D.; Choueiri, T. K. |
| Abstract Title: | Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study) |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500285 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.269 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 269 -- Source: Wos |
